Head of Manufacturing & CMC, Gene and Cell Therapy Institute
Ms. Hammill is the Head of Manufacturing and CMC for the Gene and Cell Therapy Institute at Mass General Brigham. Previously, she was co-founder of DeCART Therapeutics, Inc. and served as the Chief Operating Officer. Prior to co-founding DeCART, she served as the Director of Strategy and Business Development for the Center for Cellular Immunotherapies at the University of Pennsylvania’s Perelman School of Medicine. Notably in this role, Ms. Hammill was a member of the Executive Leadership Team and managed the Penn-Novartis alliance, which led to the FDA approval of the first CAR T cell therapy in the United States. Also at Penn, she performed in several roles at the Institute for Human Gene Therapy and Gene Therapy Program. Ms. Hammill has over 25 years of experience in translational and clinical research, specifically in cell and gene therapies, and extensive experience with start-ups, incubations and fund raising.
Ms. Hammill earned a Master of Molecular Biotechnology from the University of Pennsylvania’s School of Engineering and Applied Science with a concentration in Gene Therapy and Genetic Engineering. She earned Bachelor of Biotechnology from Rutgers University and completed the Wharton Management Program in Business Administration with honors. Ms. Hammill also earned a Master of Business Administration with a concentration in Leadership from Saint Joseph’s University. She has earned numerous certificates in GXPs and two intensive Advanced Negotiations certificates from Harvard Law School.
